Teva Pharmaceutical Industries Conference Call Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Date**: February 17, 2026 - **Focus**: Transition from a biogenerics company to a biopharma company with a focus on innovative therapies Key Industry Insights - **Market Size**: The market for ulcerative colitis (UC) and Crohn's disease (CD) is valued at approximately $38 billion, indicating significant growth potential and unmet medical needs [37] - **Pipeline Development**: Teva is advancing multiple products in its pipeline, including Duvakitug, which targets UC and CD, and has the potential to be a billion-dollar product [4][5] Core Points and Arguments 1. **Milestones for 2026**: Teva has several key milestones, including data releases for Duvakitug, IL-15 for vitiligo, and the DARI asthma program [3][22] 2. **Duvakitug Program**: - Focuses on treating UC and CD with promising Phase 2 results showing a 58% clinical remission rate for UC and a 55% endoscopic response for CD at the highest dose [14][15] - The drug is designed to block TL1A, an important inflammatory signal, and has shown a favorable safety profile with low anti-drug antibodies (3%-5%) [6][10][18] 3. **Durability of Response**: The maintenance phase data indicates a strong durability of response, which is crucial for chronic conditions like UC and CD [14][19] 4. **Competitive Landscape**: Duvakitug's efficacy is competitive with existing therapies, positioning it well in the treatment landscape for UC and CD [11][15][17] 5. **Phase 3 Trials**: Teva is moving into Phase 3 trials with a robust design, including an open-label feeder arm and subcutaneous administration, which enhances patient convenience [20][22] Additional Important Content - **Combination Therapies**: Teva is exploring combination therapies and bispecific strategies, indicating a proactive approach to enhance treatment efficacy [28][43] - **Biomarker Development**: The company is considering biomarker-enriched populations for future studies, which could lead to more targeted therapies [42][44] - **Safety Profile**: The safety profile remains consistent with previous studies, with no significant dose-dependent adverse events reported [66][67] - **Future Indications**: Teva is optimistic about the potential of TL1A beyond UC and CD, including possible effects on fibrosis [21][62] Conclusion Teva Pharmaceutical Industries is positioned for significant growth in the biopharma sector, with a strong pipeline and promising data for its lead product, Duvakitug. The company is focused on addressing unmet medical needs in chronic inflammatory diseases while exploring innovative treatment strategies and maintaining a competitive edge in the market.

Core Insights - Devonian Health Group Inc. has filed a proprietary Thykamine™ fingerprint in recent patent applications, which is a key element of its long-term intellectual property strategy [1] - The Thykamine™ fingerprint identifies eight specific chemical components in precise ratios, validated through advanced HPLC-MS methods, showing 98% confidence in batch consistency [1] - The company emphasizes the quality and consistency of Thykamine™, which has demonstrated anti-inflammatory and anti-fibrotic properties in various studies, including a Phase IIa clinical study [1] Patent Strategy - The Thykamine™ fingerprint will be systematically included in all future patent filings related to Thykamine™ [1] - This strategy aims to strengthen the company's intellectual property portfolio and regulatory preparedness for pharmaceutical development [1] Manufacturing and Quality Control - HPLC-MS methodology has shown high reproducibility across manufactured batches, confirmed by NMR analysis [1] - Potency assays using a U-937 human cell-based model validated that each batch of Thykamine™ exhibits equivalent biological activity, consistently inhibiting key inflammatory cytokines [1] Product Overview - Thykamine™, developed from Devonian's SUPREX™ platform, targets health conditions related to inflammation and oxidative stress, including ulcerative colitis and atopic dermatitis [1] - The product's anti-inflammatory, anti-oxidative, and immunomodulatory properties have been supported by numerous in vitro and in vivo studies [1] Company Background - Devonian Health Group Inc. is a clinical-stage pharmaceutical company focused on developing drugs for autoimmune fibroinflammatory diseases [1] - The company also develops high-value cosmeceutical products and operates a commercialization subsidiary, Altius Healthcare LP, for selling prescription pharmaceuticals in Canada [1]

REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the TD Cowen 46th Annual Health Care Conference, being held March 2-4, 2026, in Boston, Massachusetts. Management will participate in a fireside chat on Tuesday, March 3, 2026, at 11:50 am ET. A live webcast of the event will be available in the Investor Relations section of th ...

Core Viewpoint - The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults living with obesity, providing an additional option for weight loss after the 2.4 mg dose [1][6]. Group 1: Approval and Dosage Information - The 7.2 mg dosage can be prescribed as three 2.4 mg injections taken in one sitting, still once a week [2]. - Novo Nordisk has applied for approval of a 7.2 mg single-dose pen in the EU, which could be available this year if approved [2]. - Wegovy 7.2 mg is already approved and available in the UK, with regulatory applications pending with the US FDA and other countries [3]. Group 2: Clinical Study Results - In clinical studies STEP UP and STEP UP T2D, participants taking the 7.2 mg dose lost significantly more weight compared to those on placebo [4]. - On average, participants without diabetes lost about 21% of their body weight with Wegovy 7.2 mg, while placebo participants lost about 2% [7]. - Approximately 1 in 3 participants lost 25% or more of their body weight, with 84% of weight loss coming from fat mass while preserving muscle function [7]. Group 3: Product Information and Indications - Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight loss in adults with a BMI of 30 kg/m or greater, or 27 kg/m or greater with weight-related comorbid conditions [5]. - The injectable semaglutide is available in multiple doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and now 7.2 mg throughout the EU [4][6].

CERRITOS, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN) (“Liminatus” or the “Company”), a pre-clinical stage immuno-oncology company developing next-generation CD47-blockade therapies, today announced the pricing of its best-efforts public offering of 13,813,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 20,719,500 shares of common stock, at a combined public offering price of $0.29 per share (or $0.2899 per pre-funded ...

Core Viewpoint - Disc Medicine will pursue a traditional U.S. approval pathway for its drug bitopertin after the FDA rejected its application under a new fast-track review program [1]. Company Summary - Disc Medicine's CEO John Quisel noted that the debate over accelerated approval has evolved across multiple U.S. administrations, indicating a stricter regulatory environment for such approvals [1]. - The company anticipates late-stage data to be available in the fourth quarter of this year [1]. Industry Context - The FDA's decision to decline the fast-track approval for bitopertin was influenced by concerns regarding trial data and the potential risk for abuse [1]. - The drug was initially reviewed under the FDA's national priority voucher program, which typically shortens the approval process from 10-12 months to one to two months [1].

Core Viewpoint - Moleculin Biotech, Inc. has received a notice of allowance for a patent in Japan related to the preparation of liposomal Annamycin, which is expected to enhance its intellectual property position and support the development of its non-cardiotoxic therapy for acute myeloid leukemia [1][2][3] Group 1: Patent and Intellectual Property - The Japan Patent Office has allowed claims for a patent application covering methods for reconstituting liposomal Annamycin, ensuring consistent dosing and stability for intravenous administration [2] - This patent allowance complements existing U.S. and European patent protections, with additional applications pending in major jurisdictions worldwide [2][3] Group 2: Product Development and Clinical Trials - Annamycin, also known as naxtarubicin, is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and is positioned to be the first non-cardiotoxic anthracycline approved for clinical use [2][4] - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML [5] - Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML, as well as Orphan Drug Designation from the EMA [3][5] Group 3: Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses, with Annamycin as its lead program [4][6] - The company is also developing WP1066, an immune/transcription modulator targeting various cancers, and has a portfolio of antimetabolites for potential treatment of pathogenic viruses and certain cancer indications [6]

Last year , I initiated Madrigal Pharmaceuticals, Inc. ( MDGL ) as a Strong Buy due to the blockbuster pace of commercialization for Rezdiffra following FDA approval in March 2024. Since then, the stock has appreciated from $293 to $465, a robust gain of 58% outpacingBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior ...

Last year , I initiated Madrigal Pharmaceuticals, Inc. ( MDGL ) as a Strong Buy due to the blockbuster pace of commercialization for Rezdiffra following FDA approval in March 2024. Since then, the stock has appreciated from $293 to $465, a robust gain of 58% outpacingBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior ...

TEL AVIV, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that upcoming data for NS002, the Company’s investigational intranasal epinephrine powder formulation, will be presented at AAAAI 2026 Annual Meeting, taking place in Philadelphia, PA, USA, February 27 to March 2. “We are excited to share data highlighting NS002’s potential for supe ...